Publications by authors named "Congren Zhou"
Article Synopsis
- Stroke can cause serious health issues, leading to disability and economic burdens on families and society, prompting interest in effective treatments like the Naoshuantong capsule (NSTC) for ischemic stroke (IS).
- After reviewing 27 randomized controlled trials involving 3,139 patients, the NSTC was found to improve neurological function and long-term outcomes, while also reducing the risk of cerebrovascular disease recurrence and enhancing quality of life.
- Despite the positive results, the study noted that the certainty of evidence was moderate to very low, and there were no significant differences in adverse events between patients using the NSTC and those in the control group.
Background: Previous studies have shown contradictory results between early application of antiplatelet therapy and intravenous thrombolysis (IVT) for mild acute ischaemic stroke (AIS), with National Institutes of Health Stroke Scale score 0-5.
Objective: To compare the benefits and risks of antiplatelet therapy and IVT in patients with mild AIS.
Methods: A systematic search of MEDLINE, Embase and Cochrane Library was conducted from database inception until July 2023, without language restriction.
Stroke is the major cause of mortality and permanent disability and is associated with an astonishing economic burden worldwide. In the past few decades, accumulated evidence has indicated that Xuesaitong (XST) has therapeutic benefits in cases of acute ischemic stroke (AIS). Our study aimed to provide the best current body of evidence of the efficacy and safety of XST for patients with AIS.
View Article and Find Full Text PDF